Nuclea Biotechnologies specializes in utilizing the study of gene and protein expression to create a better understanding of the effectiveness of treatments for various diseases, including cancer and congestive heart failure. Nuclea Biotechnologies uses information on protein and gene makeup as a way to target treatments and assess their effectiveness. The company has developed innovative tests in regards to identifying patient response to treatments. These tests also aid in predicting the possibility of a recurrence of the disease.
Nuclea Biotechnologies employs technologies that allow a deeper understanding of the biology of human disease. This information helps evaluate new forms of treatment. Nuclea Biotechnologies also examines serum-based genetics, which have the potential to offer increased effectiveness when they are paired with bioimaging techniques that already exist.
Nuclea Biotechnologies addresses congestive heart failure by using protein and gene signatures to gauge the severity of heart failure and disease. The American College of Cardiology and the American Heart Association have outlined risk and survival outcomes of each stage of heart failure and/or heart disease. The stages are labeled A, B, C and D. Stage A is the least threatening, while Stage D is the most extreme. Nuclea Biotechnologies' research and testing modules focus on Stage B and C. In Stage B, there is structural damage to the heart, but no symptoms are present. In Stage C, there have b
Nuclea’s goal is to accelerate the detection and diagnosis of cancer, cardiovascular, neurological, inflammation, and metabolic disorders to the earliest stages when prevention of overt disease can be most successful. The application of Nuclea’s pioneering diagnostic assays in the practice of oncology can significantly simplify and improve the treatment decisions required by physicians.
How We Got Started
Nuclea Biotechnologies, Inc. focuses on three core capabilities:
Biomarker Discovery
